181 related articles for article (PubMed ID: 35460900)
41. Medical devices containing materials derived from animal sources (except for in vitro diagnostic devices), guidance for FDA reviewers and industry; availability--FDA. Notice.
Fed Regist; 1998 Nov; 63(215):60009-10. PubMed ID: 10187389
[TBL] [Abstract][Full Text] [Related]
42. The U.S. Food and Drug Administration's role in improving radiation dose management for medical X-ray imaging devices.
Miller DL; Kakar S; Jiang L; Spelic DC; Burk L
Br J Radiol; 2021 Oct; 94(1126):20210373. PubMed ID: 33989043
[TBL] [Abstract][Full Text] [Related]
43. Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs.
Golish SR
Trials; 2017 Jul; 18(1):348. PubMed ID: 28738891
[TBL] [Abstract][Full Text] [Related]
44. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care.
Jazowski SA; Winn AN
Curr Diab Rep; 2017 Jun; 17(6):40. PubMed ID: 28439847
[TBL] [Abstract][Full Text] [Related]
45. Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2018 Feb; 83(35):7366-88. PubMed ID: 29932613
[TBL] [Abstract][Full Text] [Related]
46. New FDA draft guidance on premarket submissions.
Donawa ME
Med Device Technol; 1999 Oct; 10(8):12-4. PubMed ID: 10724773
[TBL] [Abstract][Full Text] [Related]
47. Medical devices; exemption from premarket notification; class II devices; triiodothyronine test system. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Oct; 65(202):62285-6. PubMed ID: 11503681
[TBL] [Abstract][Full Text] [Related]
48. Medical devices; exemptions from premarket notification; class II devices. Final rule.
Food and drug Administration, HHS
Fed Regist; 2001 Nov; 66(221):57368-9. PubMed ID: 11776279
[TBL] [Abstract][Full Text] [Related]
49. Medical devices; exemption from premarket notification; class II devices; powered patient transport. Final order.
Food and Drug Administration, HHS
Fed Regist; 2013 Mar; 78(42):14015-7. PubMed ID: 23476999
[TBL] [Abstract][Full Text] [Related]
50. Medical devices; exemption from premarket notification; class II devices; wheelchair elevator. Final order.
Food and Drug Administration, HHS
Fed Regist; 2013 Mar; 78(42):14013-5. PubMed ID: 23476998
[TBL] [Abstract][Full Text] [Related]
51. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
52. Marketing approval for the lithotripter.
Nightingale SL; Young FE
Isr J Med Sci; 1986; 22(7-8):519-23. PubMed ID: 3781809
[TBL] [Abstract][Full Text] [Related]
53. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
[TBL] [Abstract][Full Text] [Related]
54. Postmarketing trials and pediatric device approvals.
Hwang TJ; Kesselheim AS; Bourgeois FT
Pediatrics; 2014 May; 133(5):e1197-202. PubMed ID: 24733871
[TBL] [Abstract][Full Text] [Related]
55. FDA regulation of invasive neural recording electrodes: a daunting task for medical innovators.
Welle C; Krauthamer V
IEEE Pulse; 2012 Mar; 3(2):37-41. PubMed ID: 22481744
[TBL] [Abstract][Full Text] [Related]
56. Regulatory aspects of invasive glucose measurements.
Gutman S; Bernhardt P; Pinkos A; Moxey-Mims M; Knott T; Cooper J
Diabetes Technol Ther; 2002; 4(6):775-7. PubMed ID: 12685800
[TBL] [Abstract][Full Text] [Related]
57. Medical devices; exemptions from premarket notification; surgical lamps--FDA. Notice.
Fed Regist; 1998 Dec; 63(233):67075-6. PubMed ID: 10338882
[TBL] [Abstract][Full Text] [Related]
58. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
59. Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations.
Zhang B; Shankara SB; Guo J; Zhang H
Contemp Clin Trials; 2022 May; 116():106757. PubMed ID: 35398250
[TBL] [Abstract][Full Text] [Related]
60. Orthopedic devices: classification and reclassification of pedicle screw spinal systems--FDA. Final rule.
Fed Regist; 1998 Jul; 63(143):40025-41. PubMed ID: 10181517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
